Ocuphire Pharma Investor Updates

4 Ocuphire Pipeline & Upcoming Milestones Multiple Phase 3 & Phase 2 Clinical Data Readouts Anticipated Over The Next Year Ocuphire-Focused Development Partnering- Focused Development Product Candidate 0.75% NyxolⓇ Eye Drop 0.75% NyxolⓇ Eye Drop APX3330 Oral Pill Indication APX2009 Intravitreal Reversal of Mydriasis (RM) 0.75% Nyxol® + Low- Dose 0.4% Pilocarpine Presbyopia (P) Eye Drops Dim Light or Night Vision Disturbances (NVD) Diabetic Retinopathy (DR)/ Macular Edema (DME) DME, Wet Age-Related Macular Degeneration (wAMD) Development Stage Pre-clinical Phase 1 Phase 2 Phase 3 Positive Data Readout Positive Data Readout Anticipated Milestones Initiated Phase 3 MIRA-2 trial 4Q20; Topline data reported in 1Q21 (n=185) Initiate Phase 3 MIRA-3 trial 2H21; Data expected in early 2022 (n=330) Initiate Pediatric trial 2H21; Data expected in early 2022 (n=20) Initiated Phase 3 LYNX-1 trial 4Q20; Data expected in 3Q21 (n=160) Initiated Phase 2 VEGA-1 trial 1Q21; Topline data reported in 2Q21 (n=150) Initiated Phase 2 ZETA-1 trial Apr21; Data expected by early 2022 (n=100) Next steps: IND enabling studies (with partner funding) Note: 0.75% Nyxol (Phentolamine Ophthalmic Solution) is the same as 1% Nyxol (Phento lamine Mesylate Ophthalmic Solution) Ocuphire PHARMA

View entire presentation